The ERISA Industry Committee Asks Ohio Legislature to Recognize Value of Proven Biosimilar Products

WASHINGTON, November 1, 2023 – The ERISA Industry Committee (ERIC) today submitted a comment letter to the Ohio House of Representatives Insurance Committee urging the panel to amend House Bill 291 to include access to all biosimilar products, a necessary step to ensure that the bill will promote competition, and drive lower drug costs for Ohioans.
“Biosimilars are safe, effective, high-quality and affordable alternatives to their reference biologics,” said Melissa Bartlett, Senior Vice President for Health Policy of ERIC.  “We support efforts to drive better patient access to these treatments, as doing so will help workers and families reduce their health care costs and maintain access to high-quality prescription drugs.”
Bartlett added that HB 291, as written, would limit access to more than 40 biosimilars available today, and agreed with the federal Food and Drug Administration (FDA) that a distinction should not be drawn between biosimilar products and “interchangeable” biosimilar products.
In 2020 ERIC launched an initiative to explore the value and savings potential of biosimilars for employers and employees, and to develop strategies to promote patient access and use of biosimilars to drive value in employer-sponsored health benefits. The ERIC Biosimilar Initiative’s three-pronged approach examined how employers, employees, and their families can realize greater benefits from the presence and utilization of biosimilar options. Read the report here.
To read ERIC’s letter to the Ohio House of Representatives Insurance Committee, click here.


All media inquiries to The ERISA Industry Committee should be directed to

About The ERISA Industry Committee
ERIC is a national advocacy organization that exclusively represents large employers that provide health, retirement, paid leave, and other benefits to their nationwide workforces. With member companies that are leaders in every sector of the economy, ERIC advocates on the federal, state, and local levels for policies that promote flexibility and uniformity in the administration of their employee benefit plans.